Search Results for keywords:"medical research"

The Drug Enforcement Administration (DEA) has announced that GGGYI LLC has applied to be registered as a bulk manufacturer of certain controlled substances, specifically marihuana, for research purposes. This application is part of DEA's program to oversee the cultivation and distribution of marihuana for scientific and medical research under strict regulations. Interested parties, such as existing manufacturers or applicants, can submit comments or objections regarding this application by April 26, 2021. The DEA will evaluate the application based on applicable laws and regulations to ensure proper safeguards against misuse are in place.

The Drug Enforcement Administration (DEA) has announced that Ohana Bio Pharma, LLC has applied to be registered as a bulk manufacturer of controlled substances in schedule I, specifically for marihuana. This application is part of a program to grow marihuana for scientific and medical research. The DEA will evaluate the application according to its regulations to ensure legal compliance and prevent any misuse. Interested parties can submit their comments or objections by May 27, 2025, through the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) has announced that Natural Fulfillment LLC has applied to become a registered manufacturer to produce controlled substances in bulk, particularly marihuana, for scientific and medical research. Interested parties, including other registered manufacturers and applicants, have until March 15, 2021, to submit their comments or raise objections to this application. If approved, Natural Fulfillment LLC will be authorized to produce bulk active pharmaceutical ingredients (APIs) for distribution to DEA-registered researchers, in compliance with all relevant laws and regulations to prevent misuse.

The Drug Enforcement Administration (DEA) is notifying the public of an application from JW Colorado, LLC, to be registered as a bulk manufacturer of marihuana, a controlled substance listed under schedule I. The DEA will evaluate the application along with others under regulations meant to ensure that the growth of marihuana is for legitimate scientific and medical research purposes. Written comments or objections to this proposed registration must be submitted by April 19, 2021, and the evaluation will ensure compliance with all relevant laws and safeguards against misuse.

The Drug Enforcement Administration (DEA) has announced that Livwell Michigan, LLC has applied to be registered as a bulk manufacturer of controlled substances, specifically marihuana, listed under Schedule I. The DEA will evaluate this application based on specific regulations and guidelines to ensure it complies with laws and has measures in place to prevent misuse. The public and other manufacturers have until April 26, 2021, to submit comments or objections regarding this application. If approved, Livwell Michigan, LLC would be allowed to produce marihuana for use in scientific and medical research, but not for other purposes.

The National Eye Institute announced a closed meeting to take place on March 25, 2021, from 12:00 p.m. to 4:30 p.m. This meeting will focus on reviewing and evaluating grant applications, specifically for the NEI Clinical Research, Secondary Data Analysis, and Conference Grant Applications. In compliance with federal law, the meeting will not be open to the public as it could reveal confidential trade secrets, patentable materials, and personal information linked to these grants. The meeting will be held virtually, and Ashley Fortress, Ph.D. serves as the designated federal official.

The National Heart, Lung, and Blood Institute announced several upcoming closed meetings to review and evaluate grant applications, related to various medical research projects. These meetings will take place virtually on different dates in March 2021 and will focus on topics like regenerative medicine, clinical trials, and mentored career development awards. The meetings are closed to the public to protect confidential information and personal privacy, as required by law. Specific contact persons are provided for each meeting, ensuring interested parties can reach out for more information.

The National Institutes of Health (NIH) has announced several upcoming meetings of the Center for Scientific Review. These meetings are part of various study groups and panels focused on evaluating grant applications related to scientific and medical research. The meetings will cover topics such as biobehavioral processes, genomics, mental function, neurodegeneration, and more. As per federal law, these meetings will be closed to the public to protect confidential information and personal privacy.